This article is more than 5 years old. Information may no longer be current.
Registry aims to classify common treatment patterns of AF
ORBIT-AF to include information on outcomes, medications and patient characteristics.
Click Here to Manage Email Alerts
The Duke Clinical Research Institute is launching a registry designed to help classify common patterns in the treatment of atrial fibrillation.
Beginning in December, researchers for the prospective, longitudinal, observational Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) will begin enrolling patients. The researchers ultimately aim to include 10,000 patients from more than 300 hospitals and clinics across the United States.
According to a press release, ORBIT-AF will provide information on patient demographics, risk profiles, insurance providers and geographical information. The aim of ORBIT-AF is to help collect information about and to describe the effects of AF on patient outcomes, costs and quality of life. The registry will also include information on the use of antithrombotic agents in the population.
“Atrial fibrillation has a significant effect on the American health care system, as it increases a patient’s risk for suffering a stroke by up to five times,” Eric Peterson, MD, associate director of the Duke Clinical Research Institute in Durham, N.C., said in a press release. “Today, very few data are available on how physicians actually treat patients with AF. We expect ORBIT-AF will provide valuable insights that could potentially improve patient care and outcomes for patients with AF.”
Enrollment for the ORBIT-AF registry will take up to two years, according to the press release. Enrolled patients will be followed prospectively on an outpatient basis with compliance and outcomes data collected at six, 12, 18 and 24 months. All adult patients with AF are eligible for enrollment.